Datopotamab deruxtecan 治疗携带可靶向基因组改变的晚期或转移性非小细胞肺癌:II期 TROPION-Lung05 研究结果
TROPION-Lung05 II期试验评估 Datopotamab deruxtecan(Dato-DXd)6 mg/kg 每3周一次治疗携带可靶向基因组改变、靶向治疗和铂类化疗后进展的晚期/转移性非小细胞肺癌(NSCLC)患者。137例可评估患者确认的客观缓解率(ORR)为35.8%(95%CI 27.8-44.4),EGFR突变和ALK重排患者分别为43.6%和23.5%,中位缓解持续时间(DOR)7.0个月,≥3级治疗相关不良事件发生率28.5%。
要点
- Dato-DXd 6 mg/kg 每3周一次在经多线治疗的晚期/转移性 NSCLC 中确认 ORR 为35.8%(95%CI 27.8-44.4)。
- EGFR突变患者确认 ORR 为43.6%(95%CI 32.4-55.3),ALK重排患者为23.5%(95%CI 10.7-41.2)。
- ≥3级治疗相关不良事件发生率为28.5%,最常见为口腔炎(任何级别56.2%;≥3级9.5%)。
核心结论
- Dato-DXd 在经重度治疗的携带可靶向基因组改变的晚期/转移性 NSCLC 中显示出令人鼓舞且持久的抗肿瘤活性。
- 治疗相关≥3级毒性发生率与既往观察相当,未观察到新的安全性信号。
研究设计与样本
- TROPION-Lung05 是一项 II 期试验(ClinicalTrials.gov 标识符:NCT04484142)。
- 纳入携带可靶向基因组改变、在靶向治疗和铂类化疗后进展的晚期/转移性 NSCLC 患者,接受 Dato-DXd 6 mg/kg 每3周一次治疗。
- 主要终点为盲法独立中心评审的客观缓解率(ORR),次要终点包括缓解持续时间(DOR)、安全性、耐受性和生存。
- 137例患者接受至少1剂 Dato-DXd,其中71.5%接受过至少三线针对晚期/转移性疾病的治疗。
- 总体中56.9%携带 EGFR 突变,24.8%携带 ALK 重排;中位治疗持续时间4.4个月(范围0.7-20.6)。
主要发现
- 总体确认 ORR 为35.8%(95%CI 27.8-44.4)。
- EGFR突变患者确认 ORR 为43.6%(95%CI 32.4-55.3),ALK重排患者为23.5%(95%CI 10.7-41.2)。
- 中位 DOR 为7.0个月(95%CI 4.2-9.8),总体疾病控制率为78.8%(95%CI 71.0-85.3)。
- ≥3级治疗相关不良事件发生于28.5%的患者。
- 最常见治疗相关不良事件为口腔炎(首选术语;任何级别56.2%;≥3级9.5%);5例(3.6%)发生经裁定的治疗相关间质性肺病/肺炎,其中1例(0.7%)为5级事件。
关键数值与推荐
- Dato-DXd 给药方案为6 mg/kg 每3周一次。
- 主要终点确认 ORR 总体为35.8%(95%CI 27.8-44.4)。
- EGFR突变患者确认 ORR 为43.6%(95%CI 32.4-55.3),ALK重排患者为23.5%(95%CI 10.7-41.2)。
- 中位 DOR 为7.0个月(95%CI 4.2-9.8),疾病控制率为78.8%(95%CI 71.0-85.3)。
- ≥3级治疗相关不良事件发生率为28.5%,口腔炎任何级别56.2%、≥3级9.5%,治疗相关间质性肺病/肺炎3.6%(5级0.7%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2-directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142) evaluated the safety and clinical activity of Dato-DXd in patients with advanced/metastatic non-small cell lung cancer (NSCLC) with actionable genomic alterations progressing on or after targeted therapy and platinum-based chemotherapy. PATIENTS AND METHODS: Patients received Dato-DXd 6 mg/kg once every 3 weeks. The primary end point was objective response rate (ORR) by blinded independent central review. Secondary end points included duration of response (DOR), safety, tolerability, and survival. RESULTS: Among 137 patients who received at least 1 dose of Dato-DXd, 71.5% received at least three lines of prior therapies for advanced/metastatic disease. Overall, 56.9% had EGFR mutations and 24.8% had ALK rearrangements. Median treatment duration was 4.4 months (range, 0.7-20.6). The confirmed ORR was 35.8% (95% CI, 27.8 to 44.4) overall, and 43.6% (95% CI, 32.4 to 55.3) and 23.5% (95% CI, 10.7 to 41.2) in those with EGFR mutations and ALK rearrangements, respectively. The median DOR was 7.0 months (95% CI, 4.2 to 9.8), and the overall disease control rate was 78.8% (95% CI, 71.0 to 85.3). Grade ≥3 treatment-related adverse events (TRAEs) occurred in 28.5% of patients. The most common TRAE was stomatitis (preferred term; any grade: 56.2%; grade ≥3: 9.5%). Five (3.6%) patients experienced adjudicated treatment-related interstitial lung disease/pneumonitis, with 1 (0.7%) grade 5 event. CONCLUSION: Encouraging and durable antitumor activity was observed with Dato-DXd in this heavily pretreated advanced/metastatic NSCLC population with actionable genomic alterations. The rate of treatment-related grade ≥3 toxicities was comparable with previous observations, and no new safety signals were observed.
引用
- Sands J, Ahn MJ, Lisberg A, et al. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol. 2025. PMID: 39761483. doi:10.1200/JCO-24-01349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。